Orthotopic injection of PDX derived cells

Intraperitoneal injection of patient-derived ascites cells

Subdermal implantation of patient sarcoma derivated cells

Subdermal implantation of patient derived endometrial or ovarian cancer tissue

Subcutaneous implantation of cancer cells derivated from patients into the flanks of mice

Subcutaneous injection of human lung cancer cells, glioblastoma cells and skin cancer cells in the flanks

Subcutaneous injection of human cholangiocarcinoma and gastric cancer cells in mice.

Tumor fragments of 3x3 mm will be implanted on the exposed mammary glands.

Orthotopic implant of Patient-Derived Cancer Cells in the cecum wall of immunodeficient mice and the methodology to monitor intestinal tumor growth using a MicroCT scan.

This mouse model was generated by crossing Ppargc1a floxed/Ppargc1b floxed mice with mice expressing Cre recombinase under the adipose-specific Adiponectin promoter (AdipoQ-Cre mice). This mouse model has a simulatenous specific deletion of the Ppargc1a and Ppargc1b genes in adipocytes, resulting in a double knockout of the genes encoding for PGC1alpha and PGC1beta in white and brown adipose tissues. The model exhibits a moderate to severe reduction in mitochodrial biogenesis in white and brown adipose tissues but do No exhibit any overt metabolic pheNoype when fed a chow or high fat diet (45% kcal from fat).